Trimethoprim - Aytu BioScience

Drug Profile

Trimethoprim - Aytu BioScience

Alternative Names: Primsol

Latest Information Update: 24 Dec 2016

Price : $50

At a glance

  • Originator Ascent Pediatrics Inc.
  • Developer Medicis Pediatrics
  • Class Antibacterials; Diaminopyrimidines
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Otitis media; Urinary tract infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2016 Aytu and Allegis Pharmaceuticals agree to co-promote trimethoprim for acute otitis media
  • 06 Oct 2015 Aytu Biosciences acquired trimethoprim oral solution from FSC Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top